{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:29:39Z","timestamp":1770485379146,"version":"3.49.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T00:00:00Z","timestamp":1490054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","drugandalcoholdependence.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.drugalcdep.2017.01.016","type":"journal-article","created":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T22:31:37Z","timestamp":1488407497000},"page":"181-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial"],"prefix":"10.1016","volume":"174","author":[{"given":"Adrian J.","family":"Dunlop","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda L.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Oldmeadow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Sadler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Ribbons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Attia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Barker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Ghijben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Hinman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1491-6218","authenticated-orcid":false,"given":"Melissa","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Lintzeris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0005","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/09595239800186961","article-title":"The pattern of intravenous drug use and associated criminal activity in patients on a methadone treatment waiting list","volume":"17","author":"Adamson","year":"1998","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0010","series-title":"Text Revision","article-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0015","series-title":"Medical Benefits Schedule","author":"Australian Government Department of Health and Ageing","year":"2009"},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0020","series-title":"Pharmaceutical Benefits Schedule","author":"Australian Government Department of Health and Ageing","year":"2009"},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0025","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1111\/j.1360-0443.2007.01979.x","article-title":"A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence","volume":"102","author":"Bell","year":"2007","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0030","series-title":"Regression Diagnostics: Identifying Influential Data and Sources of Collinearity","author":"Belsley","year":"1980"},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0035","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/clpt.1988.13","article-title":"A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts","volume":"43","author":"Bickel","year":"1988","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0040","unstructured":"Center for Substance Abuse Treatment, 2005. Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Treatment Improvement Protocol (TIP) Series 43. Substance Abuse and Mental Health Services Administration, Rockville, MD."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0045","series-title":"National Hospital Cost Data Collection: Public Sector Cost Weights For AR-DRG Version 5.2, Round 13","author":"Commonwealth of Australia","year":"2010"},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0050","series-title":"The Opiate Treatment Index (OTI) Manual","author":"Darke","year":"1991"},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0055","unstructured":"Department of Health (England) and the devolved administrations, 2007. Drug Misuse and Dependence: UK Guidelines on Clinical Management. Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive, London."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0060","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1056\/NEJM196906192802502","article-title":"Methadone treatment of randomly selected criminal addicts","volume":"280","author":"Dole","year":"1969","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0065","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s11920-007-0046-2","article-title":"Why buprenorphine is so successful in treating opiate addiction in France","volume":"9","author":"Fatseas","year":"2007","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0070","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1046\/j.1360-0443.1999.94913376.x","article-title":"Buprenorphine versus methadone maintenance for the treatment of opioid dependence","volume":"94","author":"Fischer","year":"1999","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0075","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1056\/NEJMoa022164","article-title":"Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone","volume":"349","author":"Fudala","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0080","series-title":"Economic Evaluation in Clinical Trials","author":"Glick","year":"2014"},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0085","series-title":"National Guidelines for Medication-Assisted Treatment of Opioid Dependence","author":"Gowing","year":"2014"},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0090","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/oxfordjournals.pubmed.a024606","article-title":"A shorter form health survey: can the SF-12 replicate results from the SF-36 in longitudinal studies?","volume":"19","author":"Jenkinson","year":"1997","journal-title":"J. Publ. Health Med."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0095","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1001\/jama.1992.03480200058024","article-title":"A controlled trial of buprenorphine treatment for opioid dependence","volume":"267","author":"Johnson","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0100","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0376-8716(95)01186-2","article-title":"A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence","volume":"40","author":"Johnson","year":"1995","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0105","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJM200011023431802","article-title":"A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence","volume":"343","author":"Johnson","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0110","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","article-title":"1-Year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial","volume":"361","author":"Kakko","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0115","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1017\/S0033291702006074","article-title":"Short screening scales to monitor population prevalences and trends in non-specific psychological distress","volume":"32","author":"Kessler","year":"2002","journal-title":"Psychol. Med."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0120","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2215-0366(15)00366-1","article-title":"Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study","volume":"2","author":"Kimber","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0125","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/00005053-199306000-00004","article-title":"Buprenorphine versus methadone maintenance for opioid dependence","volume":"181","author":"Kosten","year":"1993","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0130","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1046\/j.1360-0443.2002.00090.x","article-title":"A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway","volume":"97","author":"Krook","year":"2002","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0135","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.drugalcdep.2013.12.005","article-title":"The diversion and injection of a buprenorphine-naloxone soluble film formulation","volume":"136","author":"Larance","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0140","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/archpsyc.1996.01830050035005","article-title":"A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence","volume":"53","author":"Ling","year":"1996","journal-title":"Arch. Gen. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.drugalcdep.2017.01.016_bib0145","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1080\/10550490490440799","article-title":"Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial","volume":"13","author":"Lintzeris","year":"2004","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0150","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.drugalcdep.2008.08.006","article-title":"Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial","volume":"99","author":"Magura","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0155","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1046\/j.1360-0443.2003.00335.x","article-title":"Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients","volume":"98","author":"Mattick","year":"2003","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.drugalcdep.2017.01.016_bib0160","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002209.pub2","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.drugalcdep.2017.01.016_bib0165","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0170","series-title":"Monograph No. 14: Working Estimates of the Social Costs Per Gram and Per User for Cannabis, Cocaine, Opiates and Amphetamines DPMP Monograph Series","author":"Moore","year":"2007"},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0175","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0140-6736(79)91550-2","article-title":"Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong","volume":"314","author":"Newman","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0180","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0376-8716(00)80006-X","article-title":"Buprenorphine: a controlled clinical trial in the treatment of opioid dependence","volume":"60","author":"Pani","year":"2000","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0185","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0376-8716(00)00163-0","article-title":"Double-blind randomized trial of buprenorphine and methadone in opiate dependence","volume":"62","author":"Petitjean","year":"2001","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0190","series-title":"Polygon: The Many Sides to the Australian Opioid Pharmacotherapy Maintenance System","author":"Ritter","year":"2009"},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0195","series-title":"7th Annual Conference of the International Society for the Study of Drug Policy","article-title":"Planning for drug treatment services: estimating population need and demand for treatment","author":"Ritter","year":"2013"},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0200","series-title":"Counting the Costs of Crime in Australia: A 2005 Update Research and Public Policy Series No 91","author":"Rollings","year":"2008"},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0205","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/09595230500286039","article-title":"The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS)","volume":"24","author":"Ross","year":"2005","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0210","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/S0140-6736(08)60954-X","article-title":"Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial","volume":"371","author":"Schottenfeld","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0215","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1001\/archpsyc.63.1.102","article-title":"A randomized controlled trial of interim methadone maintenance","volume":"63","author":"Schwartz","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0220","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.addbeh.2015.07.030","article-title":"Bridging waitlist delays with interim buprenorphine treatment: initial feasibility","volume":"51","author":"Sigmon","year":"2015","journal-title":"Addict. Behav."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0225","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1056\/NEJMc1610047","article-title":"Interim buprenorphine vs. waiting list for opioid dependence","volume":"375","author":"Sigmon","year":"2016","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0230","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1023\/B:QURE.0000018486.91360.00","article-title":"The World Health Organization\u2019s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A Report from the WHOQOL Group","volume":"13","author":"Skevington","year":"2004","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0235","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1017\/S146114570700836X","article-title":"Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study","volume":"11","author":"Soyka","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0240","doi-asserted-by":"publisher","first-page":"23","DOI":"10.7326\/0003-4819-119-1-199307010-00004","article-title":"Dose-response effects of methadone in the treatment of opioid dependence","volume":"119","author":"Strain","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0245","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/BF02247469","article-title":"Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users","volume":"116","author":"Strain","year":"1994","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0250","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1176\/ajp.151.7.1025","article-title":"Comparison of buprenorphine and methadone in the treatment of opioid dependence","volume":"151","author":"Strain","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0255","doi-asserted-by":"publisher","first-page":"662","DOI":"10.7326\/0003-4819-148-9-200805060-00006","article-title":"Narrative review: buprenorphine for opioid-dependent patients in office practice","volume":"148","author":"Sullivan","year":"2008","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0260","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1017\/S0033291798006667","article-title":"Development of the world health organization WHOQOL-BREF quality of life assessment","volume":"28","author":"The WHO QoL Group","year":"1998","journal-title":"Psychol. Med."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0265","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000052036","article-title":"Comparison of buprenorphine and methadone in the treatment of opioid dependence","volume":"4","author":"Uehlinger","year":"1998","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0270","series-title":"Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence","article-title":"WHO department of mental health and substance abuse","year":"2009"},{"key":"10.1016\/j.drugalcdep.2017.01.016_bib0275","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2105\/AJPH.81.9.1185","article-title":"A randomized trial of an interim methadone maintenance clinic","volume":"81","author":"Yancovitz","year":"1991","journal-title":"Am. J. Publ. Health"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871617300893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871617300893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T18:52:18Z","timestamp":1536000738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871617300893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":55,"alternative-id":["S0376871617300893"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.01.016","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2017 Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}